RMTI Key Statistics, Chart & Performance
The current stock price of RMTI is 0.85 USD. In the past month the price decreased by -1.14%. In the past year, price decreased by -59.13%.
RMTI Latest News, Press Relases and Analysis
RMTI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.97 | 16.39B | ||
| SOLV | SOLVENTUM CORP | 13.58 | 13.99B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.69 | 11.58B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.51 | 5.19B | ||
| LNTH | LANTHEUS HOLDINGS INC | 10.88 | 4.30B | ||
| HAE | HAEMONETICS CORP/MASS | 16.65 | 3.74B | ||
| ICUI | ICU MEDICAL INC | 18.36 | 3.61B | ||
| XRAY | DENTSPLY SIRONA INC | 7.14 | 2.25B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.06 | 1.73B | ||
| NEOG | NEOGEN CORP | 24.9 | 1.62B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.19B | ||
| EMBC | EMBECTA CORP | 3.94 | 685.15M |
Related stock screener links
About RMTI
Company Profile
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 244 full-time employees. The firm develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The firm operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The firm is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The firm manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
Company Info
ROCKWELL MEDICAL INC
30142 Wixom Road
Wixom MICHIGAN 48393 US
CEO: Russell Ellison
Employees: 244
Phone: 18004493353
ROCKWELL MEDICAL INC / RMTI FAQ
What does ROCKWELL MEDICAL INC do?
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 244 full-time employees. The firm develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The firm operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The firm is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The firm manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
What is the current price of RMTI stock?
The current stock price of RMTI is 0.85 USD. The price increased by 2.88% in the last trading session.
Does ROCKWELL MEDICAL INC pay dividends?
RMTI does not pay a dividend.
What is the ChartMill technical and fundamental rating of RMTI stock?
RMTI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for ROCKWELL MEDICAL INC?
ROCKWELL MEDICAL INC (RMTI) currently has 244 employees.
What is the next earnings date for RMTI stock?
ROCKWELL MEDICAL INC (RMTI) will report earnings on 2026-03-18, after the market close.
RMTI Technical Analysis
RMTI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RMTI. While RMTI seems to be doing ok healthwise, there are quite some concerns on its profitability.
RMTI Financial Highlights
Over the last trailing twelve months RMTI reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS decreased by -213.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.6% | ||
| ROE | -14.9% | ||
| Debt/Equity | 0.26 |
RMTI Forecast & Estimates
8 analysts have analysed RMTI and the average price target is 3.83 USD. This implies a price increase of 350% is expected in the next year compared to the current price of 0.85.
For the next year, analysts expect an EPS growth of -750% and a revenue growth -32.86% for RMTI